The role of capillary pericytes and LRP-1 in Parkinson’s disease and dementia
Award Number
224632/Z/21/ZAward Type
Clinical Research Career Development FellowshipsStatus / Stage
ActiveDates
28 March 2022 -27 March 2026
Duration (calculated)
03 years 11 monthsFunder(s)
Wellcome TrustFunding Amount
£644,817.00Funder/Grant study page
Wellcome TrustContracted Centre
University College LondonContracted Centre Webpage
Principal Investigator
Dr Ross NortleyPI Contact
ross.nortley@ucl.ac.ukPI ORCID
0000-0001-9967-4774WHO Catergories
Understanding risk factorsUnderstanding Underlying Disease
Disease Type
Lewy body dementia (LBD)CPEC Review Info
| Reference ID | 285 |
|---|---|
| Researcher | Reside Team |
| Published | 12/06/2023 |
Data
| Award Number | 224632/Z/21/Z |
|---|---|
| Status / Stage | Active |
| Start Date | 20220328 |
| End Date | 20260327 |
| Duration (calculated) | 03 years 11 months |
| Funder/Grant study page | Wellcome Trust |
| Contracted Centre | University College London |
| Contracted Centre Webpage | |
| Funding Amount | £644,817.00 |
Abstract
(1) Parkinson’s disease (PD) / Lewy Body Dementia (DLB), where alpha-synuclein evokes ROS production and hypothesise that endothelin will be released (as observed in AD) and evoke pericyte-mediated capillary constriction to decrease cerebral blood flow.
(2) The role of APOE receptor LRP-1 in regulating increased tau phosphorylation in AD. LRP-1 is a master regulator of tau uptake/spread and highly expressed on pericytes. In AD model mice, pericyte deficiency leads to tau pathology and early neuronal loss. Thus, pericyte LRP-1 may play an important role in clearing/processing tau in the setting of amyloid pathology. I will examine whether AD-like tau pathology develops in an APP knock-in AD/pericyte-LRP-1 deficient mouse model.
(3) The effect of Covid-19 on live human pericytes and capillaries.